Longer-lasting -- times 3 Just like those guys who won't spit out their Stride gum, drugmakers love extended-release formulas of their drugs. Long-lasting versions usually have higher sales because patients prefer to take drugs less frequently. Full Article at The Money Times

A Biogen Idec shareholder is castigating CEO James Mullen (photo) for selling $85 million in company stock and picking up $63 million in compensation, Reuters reports. And no, the shareholder isn't Carl Icahn. Full Article at FiercePharma

SAN DIEGO -- (BUSINESS WIRE) -- Receptos, Inc. , a privately held biopharmaceutical company, announced the closing of a two-tranche $25 million Series A financing. Full Article at Freshnews.com

Receptos, Inc. , a privately held biopharmaceutical company, announced the closing of a two-tranche $25 million Series A financing. Full Article at News-Medical.net

Receptos, a San Diego-based biotech startup formed by a number of Biogen Idec veterans, has nailed down $25 million in venture capital to develop a vivid new way to look at certain protein structures on cells that it hopes will ultimately take a lot of... Full Article at Xconomy

One of Biogen Idec Inc.’s largest investors is criticizing chief executive James Mullen’s compensation package and other corporate spending initiatives in an effort to goad the company into boosting its stock performance. Full Article at Boston Business Journal